FZD10 and hepatocellular carcinoma: Furthermore, activation of FZD10 in liver cancer stem cells (CSCs) through METTL3-dependent N6-methyladenosine methylation enhances self-renewal, tumorigenicity, and metastasis via the FZD10-β-catenin/YAP1 axis, which is linked to drug resistance, particularly to lenvatinib, and suggests that targeting this pathway could improve treatment outcomes in HCC [120].